Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma is a research paper published in Journal of Neuro-Oncology (2023). On theSindex it has a DataRank of 1.0. It has been cited 33 times, with 32 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.529
From this paper's citation signal
Citation Network Contribution
0.510
From 27 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 32 citers.
National Institutes of Health
Grant: UM1CA137443
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: P50 CA211015
NCI NIH HHS
Grant: R01 CA279984
NCI NIH HHS
Grant: R01 CA270027
FWCI
2.82
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals